Gilead and Xilio Enter into a Sole Licensing Deal for Cancer-Targeted IL-12 Therapy

Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have announced an exclusive license agreement for the development and commercialization of Xilio's tumor-activated IL-12 program, XTX301. Xilio Therapeutics focuses on creating innovative tumor-activated immuno-oncology therapies using its proprietary platform, which includes antibodies, cytokines, bispecifics, and cell engagers. XTX301, currently in Phase 1 clinical trials for advanced solid tumors, aims to enhance anti-tumor activity while minimizing systemic side effects.

Dr. Bill Grossman from Gilead highlighted that Xilio's platform aligns with Gilead's focus on difficult-to-treat cancers, particularly through the potential of IL-12 to address various tumor types. René Russo, CEO of Xilio, expressed that Gilead's expertise would help accelerate the development of XTX301, potentially benefiting a wide range of tumors, including those that are typically resistant to immune therapies.

Under the agreement, Gilead will receive exclusive global rights to XTX301 and will provide Xilio with $43.5 million upfront, which includes a $30 million cash payment and a $13.5 million equity investment. Xilio may also receive up to $604 million in milestone payments and royalties on global net sales. Initially, Xilio will continue the clinical development of XTX301, and upon achieving specific clinical milestones, Gilead can take over the development and commercialization responsibilities, including a $75 million transition fee.

XTX301 is designed to activate within the tumor microenvironment to stimulate immunity and transform "cold" tumors into "hot" tumors, enhancing their responsiveness to treatment. The ongoing Phase 1 trial aims to evaluate its safety and effectiveness in patients with advanced solid tumors.

Xilio Therapeutics specializes in developing targeted immuno-oncology treatments to improve cancer outcomes by concentrating therapeutic effects within the tumor, thereby reducing systemic toxicity. Gilead Sciences is dedicated to advancing innovative treatments for life-threatening diseases and operates in over 35 countries globally. Both companies have expressed optimism about the potential benefits of their collaboration in advancing cancer treatment options.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!